Company / Current Assets
TherapeuticsMD, Inc. Current Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$12.3M
FY2024
5-year range
$11.8M / $128.4M
FY2020-FY2024
Trend
+3.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2024 after 4 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2024 with a 5-year CAGR of -43.3%.
Declined from $55M to $12M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -53.2%
- 5-Year CAGR
- -43.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -43.3%, indicating a declining trend.
- In FY2024, current assets increased 3.9% year-over-year.
- Peak current assets was recorded in FY2019.
- Lowest current assets in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.3M | +3.9% |
| FY2023 | $11.8M | -78.7% |
| FY2022 | $55.4M | -53.7% |
| FY2021 | $119.5M | -7.0% |
| FY2020 | $128.4M | -38.4% |
| FY2019 | $208.4M | +11.6% |
| FY2018 | $186.8M | +33.8% |
| FY2017 | $139.6M | +0.1% |
| FY2016 | $139.4M | +97.2% |
| FY2015 | $70.7M | +25.7% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026